| Literature DB >> 35051706 |
Manisha Nidhar1, Shaziya Khanam1, Priyanka Sonker1, Priya Gupta2, Archisman Mahapatra2, Swaraj Patil3, Brijesh Kumar Yadav1, Rahul Kumar Singh2, Ashish Kumar Tewari4.
Abstract
This work presented the first report on designing, synthesizing of novel pyrazole-triazole-persulfonimide (7a-i) and pyrazole-triazole-aryl derivatives (8a-j) via click reaction using CuI catalyst and evaluated for their anti-diabetic activity and DPP-4 inhibitory effect. Click reactions went smoothly with CuI catalyst in the presence of tridentate chelating ligands and produced copper-free target pyrazole-triazole-persulfonimide analogues in excellent yield at RT. The designed compounds were docked against DPP-4 enzyme and showed excellent interaction with active amino acids residue. Further, all novel pyrazole-triazole-persulfonimide and pyrazole-triazole derivatives were subjected to enzyme-based in vitro DPP-4 inhibitory activity. Based on the SAR study DPP-4 inhibitory capacity compounds 7f (9.52 nM) and 8h (4.54 nM) possessed the significant inhibition of DPP-4. Finally compounds 7f and 8h were evaluated for their in vivo anti-diabetic activity using STZ induced diabetic mice model, and 8h showed a significant diabetic control effect compared to the sitagliptin drug. These studies demonstrated that the novel pyrazole-triazole-persulfonimide and pyrazole-triazole-aryl derivatives might be used as the leading compounds to develop novel DPP-4 inhibitors as potential anti-diabetic agents.Entities:
Keywords: Anti-diabetic activity; Click reaction; DPP-4 inhibitors; Docking study; Pyrazole-triazole-persulfonimides
Mesh:
Substances:
Year: 2022 PMID: 35051706 DOI: 10.1016/j.bioorg.2021.105586
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275